Ultrasound-guided thermal ablation for treating papillary thyroid cancer
The Clinical Outcomes of Ultrasound-guided Thermal Ablation for the Treatment of Papillary Thyroid Carcinoma: A Multicenter Study
This study is testing whether ultrasound-guided thermal ablation can safely and effectively treat small papillary thyroid cancers in patients with less aggressive disease over a follow-up period of at least a year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese PLA General Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06733740 on ClinicalTrials.gov |
What this trial studies
This study evaluates the long-term outcomes of ultrasound-guided thermal ablation as a treatment for papillary thyroid carcinoma. It is a multicenter observational study that aims to predict clinical outcomes for patients undergoing this procedure. The study focuses on patients with small tumors and no evidence of aggressive cancer characteristics. Data will be collected over a follow-up period of at least 12 months to assess effectiveness and safety.
Who should consider this trial
Good fit: Ideal candidates are patients aged 18 to 80 with confirmed papillary thyroid carcinoma measuring 2.0 cm or less, without aggressive features.
Not a fit: Patients with aggressive forms of thyroid cancer or significant comorbidities may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this approach could provide a less invasive treatment option for patients with papillary thyroid carcinoma.
How similar studies have performed: Other studies have shown promising results with ultrasound-guided thermal ablation for similar conditions, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. patients age between 18 and 80 year old, both sex 2. papillary thyroid carcinoma confirmed by core-needle biopsy or fine-needle aspiration 3. the largest diameter ≤2.0 cm 4. no clinical or imaging evidences of extrathyroidal extension, lymph node metastasis and distant metastasis on ultrasound, neck and chest CT 5. follow-up period ≥12 months Exclusion Criteria: 1. patients with convincing evidence of aggressive papillary thyroid carcinoma or other type of thyroid cancer by biopsy 2. history of neck radiation 3. coagulation disorder, serious heart, respiratory, liver, or renal failure 4. dysfunction of the vocal cord on the opposite side
Where this trial is running
Beijing, Beijing Municipality
- Chinese PLA General Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Yukun Luo — Chinese PLA General Hospital
- Study coordinator: Lin Yan, MD
- Email: gemma-y@163.com
- Phone: 13811237313 ext 86
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.